Lin HM, Davis KL, Kaye JA, Luptakova K, Nagar SP, Mohty M. Real-world treatment patterns, outcomes, and healthcare resource utilization in relapsed or refractory multiple myeloma: evidence from a medical record review in France. Adv Hematol. 2019 Jan 29;2019(4625787). doi: 10.1155/2019/4625787
Davis KL, Cote I, Kaye JA, Mendelson E, Gao H, Perez Ronco J. Real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib. Adv Hematol. 2015 Oct;2015(2015):848473. doi: 10.1155/2015/848473
Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014 Apr;22(2):96-101. doi: 10.3109/09273948.2013.812222
Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012 Feb;20(1):18-26. doi: 10.3109/09273948.2011.633205.
Umscheid CA, Maguire MG, Pines JM, Everett WW, Baren JM, Townsend RR, Mines D, Szyld D, Gross R. Untreated hypertension and the emergency department: a chance to intervene? Acad Emerg Med. 2008 Jun;15(6):529-36. doi: 10.1111/j.1553-2712.2008.00132.x
Umscheid CA, Maguire MG, Pines JM, Everett WW, Baren JM, Townsend RR, Mines D, Szyld D, Gross R. The prevalence of and risk factors associated with untreated hypertension in ED patients. Poster presented at the 2007 Society for Academic Emergency Medicine Conference; May 2007. Chicago, IL. [abstract] Acad Emerg Med. 2007; 14(5 Suppl 1):S117.